А contemporary view on the treatment of pain in patients with Parkinson's disease
Keywords:
Parkinson's disease, painAbstract
Pain is one of the most frequently reported non-motor symptoms in Parkinson's disease (PD) with a significant impact on patients' quality of life. Pain can be related and non-related to the disease (due to secondary diseases). The etiology of pain is multifactorial, but despite the accumulated data in recent years, the exact pathophysiological mechanisms are still not fully understood. On the other hand, pain is still underdiagnosed in routine clinical practice. Currently, there is no evidence-based consensus for the treatment of PD-related pain. The recommendations are mainly based on algorithms for the treatment of pain in other diseases. Along with optimizing dopaminergic therapy, other pharmacological and non-pharmacological strategies may be helpful.
References
Bruno, V., Freitas, M.E., Mancini, D., Lui, J.P., Miyasaki, J., Fox, S.H. Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease. Can J Neurol Sci, 2018, 45, 1, 23-29.
Buhmann, C., Kassubek, J., Jost, W.H. Management of Pain in Parkinson’s Disease. J. Parkinsons. Dis., 2020, 10, S37–S48.
Buhmann, C., Wrobel, N., Grashorn, W. et al. Pain in Parkinson disease: a crosssectional survey of its prevalence, specifics, and therapy. J Neurol, 2017, 264, 758–769.
Carbone, F., Djamshidian, A., Seppi, K., Poewe, W. Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs, 2019, 33, 9, 905–918.
Cattaneo, C., Barone, P., Bonizzoni, E., Sardina, M. Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. J. Parkinsons Dis., 2017, 7, 1, 95–101.
Cattaneo, C., Kulisevsky, J., Tubazio, V., Castellani, P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv. Ther., 2018, 35, 4, 515–522.
Chaudhuri, K. R., Odin, P., Ferreira, J. J., Antonini, A., Rascol, O., Kurtis, M. M., Storch, A., Bannister, K., Soares-da-Silva, P., Costa, R., Magalhães, D., & Rocha, J. F. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial. BMC neurology, 2022, 22, 1, 88.
Chaudhuri, K.R., Rizos, A., Trenkwalder, C. et al. King’s Parkinson’s disease pain scale, the first scale for pain in PD: An international validation. Mov Disord, 2015, 30, 1623–1631.
Dellapina, E., Gerdelat-Mas, A., Ory-Magne, F., Pourcel, L., Galitzky, M., Calvas, F. et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov. Disord. Off. J. Mov. Disord. Soc., 2011, 26, 1, 153–157.
Djaldetti, R., Yust-Katz, S., Kolianov, V., Melamed, E., Dabby, R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin. Neuropharmacol., 2007, 30, 4, 201–205.
Edinoff, A., Sathivadivel, N., McBride, T., Parker, A., Okeagu, C., Kaye, A. D., Kaye, A. M., Kaye, J. S., Kaye, R. J., M Sheth, M., Viswanath, O., & Urits, I. Chronic Pain Treatment Strategies in Parkinson's Disease. Neurology international, 2020, 12, 3, 61–76.
Freo, U., Furnari, M., Ori, C.. Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson’s disease. J. Pain Res., 2018, 11, 1849–1856.
Geroin, C., Di Vico, I.A., Squintani, G., Segatti, A., Bovi, T., Tinazzi, M. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J. Neural. Transm., 2020, 127, 8, 1143–1152.
Ghosh, P., Imbriani, P., Caputi, N., Natoli, S., Schirinzi, T., Di Lazzaro, G. et al. A dual Centre study of pain in Parkinson’s disease and its relationship with other non-motor symptoms. J. Parkinsons Dis., 2020, 10, 4, 1817–1825.
Grigoriou, S., Martínez-Martín, P., Chaudhuri K.R., Rukavina, K., Leta, V., Hausbrand, D, Falkenburger, B., Odin, P., Reichmann, H. Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain Behav. 2021, 11, 10, e2336.
Iwaki, H., Ando, R., Tada, S., Nishikawa, N., Tsujii, T., Yamanishi, Y., et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson’s disease. J. Neurol. Sci., 2020, 414, 116833.
Kassubek, J., Chaudhuri, K.R., Zesiewicz, T. et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol, 2014, 14, 42.
Lawn, T., Aman, Y., Rukavina, K., et al. Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer’s Disease and Parkinson’s Disease. Pain, 2021, 162, 999–1006.
Li, D., Song, X., Huang, H., Huang, H., Ye, Z. Association of Parkinson’s disease related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-alpha. Neurosci. Lett., 2018, 683, 181–184.
Li, T., Wang, T., Wang, L., Liu, R., Zhang, L., Zhai, R., et al. Antinociceptive effects of rotigotine-loaded microspheres and its synergistic interactions with analgesics in inflammatory pain in rats. Eur. J. Pharmacol., 2021, 891, 173693.
Martinez-Martin, P., Rodriguez-Blazquez, C., Kurtis, M.M., et al. The impact of nonmotor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord, 2011, 26, 399–406.
Mylius, V., Perez Lloret, S., Cury, R.G., et al. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain, 2021, 162, 4, 1201-1210.
Postuma, R.B., Berg, D., Stern, M., et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord, 2015, 30, 1591–1601.
Rascol, O., Zesiewicz, T., Chaudhuri, K.R., et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain. J Clin Pharmacol, 2016, 56, 852–861.
Rukavina, K., Cummins, T.M., Chaudhuri, K.R., Bannister, K. Pain in Parkinson's disease: Mechanism-based treatment strategies. Curr Opin Support Palliat Care, 2021,15, 2, 108-115.
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S.H., Katzenschlager, R., Perez Lloret, S., et al.. Update on treatments for nonmotor symptoms of Parkinson’s diseasean evidence-based medicine review. Mov. Disord. Off. J. Mov. Disord. Soc., 2019, 34, 2, 180–198.
Stoyanova-Piroth, G., Milanov, I., & Stambolieva, K. Translation, adaptation and validation of the Bulgarian version of the King's Parkinson's Disease Pain Scale. BMC neurology, 2021, 21, 1, 357.
Trenkwalder, C., Chaudhuri, K.R., Martinez-Martin, P., Rascol, O., Ehret, R., Valis, M., et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebocontrolled trial. Lancet Neurol., 2015, 14, 12, 1161–1170.
Trenkwalder, C., Kies, B., Rudzinska, M., et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord, 2011, 26, 90–99.
Wasner, G., Deuschl, G. Pains in Parkinson disease--many syndromes under one umbrella. Nat Rev Neurol., 2012, 17, 8, 5, 284-94.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Movement Disorders
This work is licensed under a Creative Commons Attribution 4.0 International License.
